The Daily7 Sep 2023

Why One Drug Company Held Back a Better Drug

For decades, drugmakers have argued that patents are critical to bringing new drugs to the market. But in 2004, when a promising H.I.V. treatment emerged, Gilead Sciences decided to slow-walk its release to maximize profit on the company’s existing patents.

Rebecca Robbins, who covers the pharmaceutical industry for The Times, discusses one man’s case and how patents can create perverse incentives to delay new and better drugs.

Guest: Rebecca Robbins, a business reporter covering the pharmaceutical industry for The New York Times.

Background reading:

Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents showed.
In August, an expert panel recommended the new daily pill Descovy for H.I.V. prevention.

For more information on today’s episode, visit nytimes.com/thedaily. Transcripts of each episode will be made available by the next workday.

Subscribe today at nytimes.com/podcasts or on Apple Podcasts and Spotify. You can also subscribe via your favorite podcast app here https://www.nytimes.com/activate-access/audio?source=podcatcher. For more podcasts and narrated articles, download The New York Times app at nytimes.com/app.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(2936)

The Tangled Tale of the Tate Brothers and the Trumps

Warning: This episode contains strong language. Over the past decade, the Tate brothers have built a global empire around pornography, hypermasculinity and overt misogyny. At the same time, they have ...

3 Aug 39min

After Losing Her Limbs, Our Cooking Columnist Returns to the Kitchen

For decades, the kitchen was the centerpiece of Yewande Komolafe’s life. She spent long hours there, first as a restaurant cook and later as a recipe developer. But though she loved the often-intense ...

2 Aug 31min

The Fight Tearing Apart Silicon Valley

For years, a debate has been simmering in Silicon Valley over the right way to build artificial intelligence. Should it be open and free for anyone to use, or should we tightly control how it’s made a...

31 Jul 26min

Europe Is Burning

This summer, wildfires have been raging across Europe. France and Spain have been hit particularly badly, with hundreds of thousands of acres incinerated and entire communities devastated. Chico Harla...

30 Jul 29min

Israel, AIPAC and Difficult Questions for Democrats

The American Israel Public Affairs Committee, a pro-Israel lobbying group known as AIPAC, has spent a record amount of money in this year’s midterm elections to either oust or support candidates based...

29 Jul 39min

The Iranians Who Want More War

Fractures in Tehran are pitting a faction favoring negotiation with Washington against hard-liners who oppose making a deal with the United States. Guest: Abdi Latif Dahir, a Middle East correspond...

28 Jul 29min

What A.I. Is Actually Doing to the Economy

As artificial intelligence becomes more advanced, people are getting more nervous about how it could change the economy and their jobs. Ben Casselman, the chief economics correspondent for The New Yor...

27 Jul 34min

Why Do Some Memories Survive Dementia?

When the Times reporter Ellen Barry’s father developed dementia after a fall, her family spent years trying to manage his erratic behavior and confusion. They struggled to convince him that he was hom...

26 Jul 29min